STOCKS TELEGRAPH

Tag: NASDAQ: CELU

  • 3 Stocks That Could See Movement: Celularity (CELU), Ernexa Therapeutics (ERNA), Cardiol Therapeutics (CRDL)

    3 Stocks That Could See Movement: Celularity (CELU), Ernexa Therapeutics (ERNA), Cardiol Therapeutics (CRDL)

    Investor focus on emerging biotech and medical technology companies has increased amid growing interest in innovative treatments and next-generation healthcare solutions. As companies move through various stages of clinical and commercial development, market participants continue evaluating both near-term catalysts and long-term growth opportunities.

    Celularity Inc (CELU)

    Celularity Inc (NASDAQ: CELU) opened trading on May 19, 2026, with great promise as it jumped 0.96% to $0.81. During the day, the stock rose to $0.82 and sank to $0.78. Taking a long-term approach, CELU posted a 52-week range of $0.71-$4.35.

    The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded 49.85%. Meanwhile, its Annual Earnings per share during the time was 49.85%.  This publicly-traded company’s shares outstanding now amount to $28.84 million, simultaneously with a float of $11.57 million. The organization now has a market capitalization of $23.33 million.

    Ernexa Therapeutics Inc (ERNA)

    Ernexa Therapeutics Inc (NASDAQ: ERNA) started the day on May 19, 2026, with a price decrease of -6.53% at $11.45. During the day, the stock rose to $12.03 and sank to $10.50. Taking a long-term approach, ERNA posted a 52-week range of $3.18-$93.75.

    It was noted that the giant of the Healthcare sector posted annual sales growth of 69.90% over the last 5 years. Meanwhile, its Annual Earnings per share during the time was 69.90%.  Nevertheless, the stock’s Earnings Per Share (EPS) this year is 83.22%. This publicly-traded company’s shares outstanding now amount to $1.17 million, simultaneously with a float of $0.68 million. The organization now has a market capitalization of $13.35 million.

    Cardiol Therapeutics Inc. (CRDL)

    Cardiol Therapeutics Inc. (NASDAQ: CRDL) is continuing to build a broader cardiovascular growth strategy through the development of next-generation therapies aimed at large and underserved disease markets. By expanding beyond recurrent pericarditis, the company is positioning itself to address chronic cardiac conditions where inflammation and fibrosis contribute significantly to disease progression.

    Market Momentum

    As of May 19, 2026, CRDL closed at $1.26, down 1.56%, with trading volume of 233,010 shares compared to an average volume of 685,872 shares. The company currently maintains a market capitalization of $145.243M and a beta of 0.43, reflecting relatively moderate volatility for a small-cap biotech company. Shares continue trading within their 52-week range of $0.8800 to $1.71, while the 1-year target estimate of $7.35 suggests substantial upside potential tied to future pipeline advancement and clinical milestones.

    Pipeline Development: CRD-38

    Cardiol is developing CRD-38, a proprietary subcutaneous therapy designed to improve dosing convenience while expanding applicability into broader cardiovascular indications, including heart failure. The therapy is intended to target inflammation and fibrosis, biological mechanisms strongly associated with worsening cardiac function and progressive heart disease.

    Large Market Opportunity

    Heart failure remains one of the largest cardiovascular markets globally, affecting millions of patients and generating substantial healthcare costs annually. Despite multiple approved therapies, unmet need persists for treatments capable of directly addressing inflammatory and fibrotic pathways associated with disease progression and long-term cardiac decline.

    Outlook

    As CRD-38 advances toward future clinical development, the program could emerge as an important secondary value driver for Cardiol. Continued progress across the broader pipeline may strengthen the company’s strategic positioning within cardiovascular biotechnology.

  • Celularity (CELU) Stock Suffered A Setback

    Celularity (CELU) Stock Suffered A Setback

    Celularity Inc. (Nasdaq: CELU) experienced a notable setback, witnessing a 6.71% decline in its stock price, culminating in a closing figure of $0.2112 during the previous trading session.

    Of equal significance, the trading volume of Celularity stock on the day significantly undershot the established average, recording a mere 0.26 million shares traded, in contrast to the customary daily average of 0.56 million shares.

    This decline in CELU stock value can be directly attributed to an internal transaction wherein a prominent stakeholder divested approximately 55% of their holdings in the company.

    Sorrento Therapeutics, Inc. holds a substantial 10% stake in Celularity (CELU).

    The most recent insider transaction involving Sorrento took place on October 5, 2023, during which Sorrento proceeded to sell a substantial 6,307,158 shares of CELU’s Class A Common Stock, leading to a reduction of their ownership stake by more than 55%. Consequently, Sorrento’s current holdings in CELU amount to 5.05 million shares.

    Celularity is a prominent biotechnology enterprise specializing in the advancement of allogeneic cell therapies and cutting-edge biomaterial products.

    Notably, CELU has recently embarked on a protracted Research Collaboration Services Agreement with the esteemed Regeneron Pharmaceuticals. This strategic partnership is aimed at bolstering Regeneron’s research endeavors in the realm of allogeneic cell therapy.

    The initial emphasis of this agreement is centered on the exploration of a specialized allogeneic gamma delta chimeric antigen receptor (CAR) T-cell therapy, an intellectual property of Regeneron. This therapeutic approach is meticulously engineered to augment proliferation and potency in combating solid tumors.

    The research will be conducted at CELU’s state-of-the-art facility, which is conveniently situated in Florham Park, New Jersey. However, financial particulars of this collaboration remain undisclosed.

    This collaborative alliance with Regeneron signifies a significant milestone for Celularity, underscoring its prowess in the domain of cellular therapies, particularly in the domain of CAR-T cell engineering.

    It paves the way for potential future collaborations within the industry, capitalizing on CELU’s exceptional cell therapy infrastructure and capabilities.

    CELU management has long held a deep respect for the outstanding scientific heritage of Regeneron which resulted in them eagerly welcome the opportunity to cooperate with a global leader in groundbreaking pharmaceutical innovation.